• A Bewley, R Cerio, M Clement, S Hunt, T Lucke, R Ratnavel, S Walton, and F Percival.
• Department of Dermatology, Whipps Cross Hospital, London, UK. anthony.bewley@whippsx.nhs.uk
• Clin. Exp. Dermatol. 2011 Aug 1; 36 (6): 602-6.

BackgroundPsoriasis affects 1-2% of the U.K. population, with 20-30% of those affected having severe psoriasis managed with systemic therapies. Biological agents are a useful option when other systemic therapies have failed. The National Institute for Health and Clinical Excellence (NICE) in the U.K. has published three sets of guidance relating to the use of biological agents.AimTo establish whether biological agents were being used in line with NICE guidance.MethodsThe study was conducted in seven specialist dermatology units, and involved the retrospective collection of data from patients treated with biological agents since the introduction of the NICE guidance.ResultsIn total, 176 patients with 212 episodes of treatment were included in the study. Biologics were started for appropriately severe disease in 85% of cases (n = 180) and only after failure, intolerance or contraindication to standard systemic therapies in 97% of cases (n = 206). Etanercept was discontinued appropriately in responders before week 24 in only 12% (five of 60 responders). Across all agents, 40% (72 of 178 with continuity status) were continued on treatment despite not achieving an adequate response according to NICE criteria.ConclusionsIn the seven sites audited, compliance with national guidance was entirely appropriate in terms of therapy initiation; however, the requirement to discontinue etanercept in responders was rarely followed. Similarly, discontinuation of biologicals in nonresponders was not routine practice. This may indicate a reluctance of both patients and clinicians to withdraw an at least partly effective therapy from these refractory patients.© The Author(s). CED © 2011 British Association of Dermatologists.

16 keywords...

hide…